8,078 Agilent Technologies, Inc. $A Shares Sold by Formuepleje A S

Formuepleje A S lessened its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 27.2% during the third quarter, Holdings Channel.com reports. The fund owned 21,641 shares of the medical research company’s stock after selling 8,078 shares during the period. Formuepleje A S’s holdings in Agilent Technologies were worth $3,729,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in A. Bank of New York Mellon Corp lifted its position in Agilent Technologies by 87.4% during the second quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company’s stock worth $695,227,000 after purchasing an additional 2,440,360 shares during the period. Legal & General Group Plc bought a new stake in Agilent Technologies during the second quarter worth $260,101,000. Bank of America Corp DE bought a new stake in Agilent Technologies during the second quarter worth $213,269,000. Man Group plc bought a new stake in Agilent Technologies during the second quarter worth $179,257,000. Finally, Primecap Management Co. CA acquired a new stake in shares of Agilent Technologies in the 2nd quarter valued at $176,318,000. Institutional investors own 87.41% of the company’s stock.

Trending Headlines about Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Analysts raised their targets: Morgan Stanley increased its target from $175 to $190 and maintained an “overweight” rating. TD Cowen raised its target from $180 to $196 and upgraded or maintained the stock at “buy.” The revisions signal expectations for continued earnings growth and approximately 9%–12% potential upside from recent trading levels. Morgan Stanley Forecasts Strong Price Appreciation for Agilent Technologies Stock TD Cowen Adjusts Price Target on Agilent Technologies
• Positive Sentiment: Proscia acquisition expands Agilent’s digital-health strategy: Agilent agreed to acquire pathology software company Proscia for $240 million upfront, with total consideration potentially reaching $270 million through milestone payments. Proscia’s AI-enabled digital pathology technology could broaden Agilent’s offerings and provide exposure to software-driven diagnostics and scientific intelligence. Agilent Technologies to Acquire Proscia
• Positive Sentiment: Favorable industry backdrop: A market report projects a 17.3% compound annual growth rate for global metabolomics through 2030, potentially supporting demand for Agilent’s analytical instruments and AI-enabled laboratory solutions. Global Metabolomics Market Report 2026
• Neutral Sentiment: China expansion: Agilent plans to expand its capabilities in China, which could create longer-term growth opportunities but also leaves the company exposed to regional regulatory, competitive and geopolitical risks. Agilent to Expand Capabilities in China
• Negative Sentiment: Investors will monitor acquisition execution: The Proscia transaction adds spending and integration obligations, and its benefits may take time to materialize. The deal’s ultimate value could rise to $270 million if milestones are achieved.

Analysts Set New Price Targets

A has been the topic of several recent analyst reports. Citigroup lifted their price target on Agilent Technologies from $185.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, August 27th. Sanford C. Bernstein upped their price objective on Agilent Technologies from $155.00 to $180.00 and gave the stock an “outperform” rating in a research report on Thursday, August 27th. JPMorgan Chase & Co. upped their price objective on Agilent Technologies from $180.00 to $190.00 and gave the stock an “overweight” rating in a research report on Thursday, August 27th. TD Cowen raised their price objective on Agilent Technologies from $180.00 to $196.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Jefferies Financial Group started coverage on Agilent Technologies in a research report on Thursday, July 9th. They issued a “hold” rating and a $135.00 target price on the stock. Fifteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Agilent Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $173.65.

Insider Transactions at Agilent Technologies

In related news, Director Mikael Dolsten sold 634 shares of Agilent Technologies stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $151.38, for a total transaction of $95,974.92. Following the sale, the director directly owned 4,924 shares in the company, valued at $745,395.12. This trade represents a 11.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.17% of the stock is currently owned by company insiders.

Agilent Technologies Price Performance

Agilent Technologies stock traded up $2.16 during mid-day trading on Thursday, reaching $176.16. The company had a trading volume of 441,599 shares, compared to its average volume of 2,257,792. The business has a fifty day simple moving average of $157.78 and a 200 day simple moving average of $136.84. The company has a market cap of $49.66 billion, a P/E ratio of 34.61, a P/E/G ratio of 2.61 and a beta of 1.21. Agilent Technologies, Inc. has a fifty-two week low of $108.35 and a fifty-two week high of $177.05. The company has a current ratio of 2.05, a quick ratio of 1.56 and a debt-to-equity ratio of 0.50.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.13. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. The company had revenue of $1.88 billion during the quarter, compared to the consensus estimate of $1.84 billion. During the same period in the prior year, the business earned $1.37 earnings per share. The company’s revenue for the quarter was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, equities research analysts predict that Agilent Technologies, Inc. will post 6.20 earnings per share for the current year.

Agilent Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 28th. Investors of record on Tuesday, October 6th will be issued a $0.2550 dividend. This represents a $1.02 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Tuesday, October 6th. Agilent Technologies’s dividend payout ratio (DPR) is 20.08%.

Agilent Technologies Profile

Agilent Technologies, Inc is an analytical measurement and laboratory technology company serving the life sciences, diagnostics, pharmaceutical, chemical, environmental, food, energy and academic research markets. Its solutions help laboratories analyze the composition, quality and performance of materials, biological samples and other substances.

The company’s products and services include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy equipment, laboratory automation tools, software, consumables and supplies.